89,95 €
89,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
45 °P sammeln
89,95 €
89,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
45 °P sammeln
Als Download kaufen
89,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
45 °P sammeln
Jetzt verschenken
89,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
45 °P sammeln
  • Format: PDF

This book concentrates on the biostatistics component of clinical trials. This new, second edition is updated throughout and includes three new chapters. This text reflects the academic research, commercial development, and public health aspects of clinical trials.

Produktbeschreibung
This book concentrates on the biostatistics component of clinical trials. This new, second edition is updated throughout and includes three new chapters. This text reflects the academic research, commercial development, and public health aspects of clinical trials.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Weichung Joe Shih, PhD, has been tenured professor and chair of the Department of Biostatistics, Rutgers School of Public Health, Rutgers University, New Brunswick, New Jersey, and director of Biometrics Division at the Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. He is an elected fellow of the American Statistical Association (1996) and an elected member of the International Statistical Institute (2001). Prior to joining academia, he spent his formative years (1982-1999) at Merck Research Laboratories, Rahway, New Jersey. He served in the Advisory Board of the US FDA for reviewing new drug applications, and was associate editor of professional journals, including Statistics in Medicine, Controlled Clinical Trials, Clinical Cancer Research, Statistics in Biopharmaceutical Research, and Statistics in Bioscience. He pioneered in the field of sample size re-estimation for clinical trials, which has evolved into the field of adaptive designs. He also first advocated the use of consistency criterion for international bridging studies, which is now adopted by the ICH guidance for global multiregional clinical trials. He has collaborated extensively with physicians in various therapeutic areas and authored numerous papers in statistical methodology in clinical trials. His research interests include adaptive designs and missing data issues. He has been honored as professor emeritus of Rutgers University since July 2019.

Joseph Aisner, MD, is a professor of medicine and a professor of environmental and occupational medicine at the Robert Wood Johnson Medical School of Rutgers University, New Brunswick, New Jersey, director of Medical Oncology Unit at the Robert Wood Johnson University Hospital, New Brunswick, New Jersey, and co-leader of the Clinical Investigations Program at the Rutgers Cancer Institute of New Jersey. He has published extensively and has served on the editorial board of multiple journals, including Journal of Clinical Oncology, Cancer Therapeutics, Medical Oncology, Clinical Cancer Research, and Hematology-Oncology Today. He is a fellow of the American College of Physicians and the American Society of Clinical Oncology. He serves on and chairs several National Data Monitoring Committees, has served on multiple National Institutes of Health (NIH) Study Sections, and has headed two National Cooperative Cancer Study Groups. His research interests include cancer clinical trials and evaluation of therapeutic interventions.

Rezensionen
"This book gives a good overview a bout various aspects of statistics in the design, monitoring and analysis of clinical trials and covers also modern topics. In my opinion this book can not only be helpful for teaching, but could also be a very helpful guidebook for inexperienced statistic ians as well as other researchers who are just starting to work in the field of clinical trials. It may also be a good tool to help the communication between multidisciplinary trial teams, as it covers the topics from several angles and does not purely foc us on statistics."

- Stefanie Hayoz, ISCB News, September 2022.